Members Only Content
Subscribe to get full access
Free Preview
The RNAi-based drug developer snagged up to $240 million, including $180 million upfront, for an asset it doesn't own.
Upstart Recommendation Report Upstart Presentation Slides
Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]
PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]
